共 50 条
- [1] A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumoursBRITISH JOURNAL OF CANCER, 2020, 123 (10) : 1481 - 1489Le Tourneau, ChristopheDelord, Jean-PierreKotecki, NuriaBorcoman, EdithGomez-Roca, CarlosHescot, SegoleneJungels, ChristianeVincent-Salomon, AnneCockenpot, VincentEberst, LaurianeMole, AudreyJdey, WaelBono, FrancoiseTrochon-Joseph, VeroniqueToussaint, HeleneZandanel, ChristelleAdamiec, Olgade Beaumont, OlivierCassier, Philippe Alexandre
- [2] Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)Le Tourneau, ChristopheDelord, Jean-PierreCassier, PhilippeKotecki, NuriaBorcoman, EdithHescot, SegoleneJungels, ChristianeMole, AudreyToussaint, HeleneAdamiec, Olgade Beaumont, Olivier
- [3] First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid TumorsCLINICAL CANCER RESEARCH, 2012, 18 (17) : 4806 - 4819Martinez-Garcia, MariaBanerji, UdaiAlbanell, JoanBahleda, RastilavDolly, SaoirseKraeber-Bodere, FrancoiseRojo, FedericoRoutier, EmilieGuarin, ErnestoXu, Zhi-XinRueger, RuedigerTessier, Jean J. L.Shochat, EliezerBlotner, SteveNaegelen, Valerie MeresseSoria, Jean-Charles
- [4] A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Langleben, AdrianSupko, Jeffrey G.Hotte, Sebastien J.Batist, GeraldHirte, Hal W.Rogoff, HarryLi, YouzhiLi, WeiKerstein, DavidLeggett, DavidHitron, Matthew J.Li, Chiang
- [5] Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialBritish Journal of Cancer, 2019, 121 : 318 - 324Zachary W. VeitchDavid W. CesconTrisha DennyLisa-Maria YonemotoGraham FletcherRichard BrokxPeter SampsonSze-Wan LiTrevor J. PughJeffrey BruceMark R. BrayDennis J. SlamonTak W. MakZev A. WainbergPhilippe L. Bedard
- [6] Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialBRITISH JOURNAL OF CANCER, 2019, 121 (04) : 318 - 324Veitch, Zachary W.Cescon, David W.Denny, TrishaYonemoto, Lisa-MariaFletcher, GrahamBrokx, RichardSampson, PeterLi, Sze-WanPugh, Trevor J.Bruce, JeffreyBray, Mark R.Slamon, Dennis J.Mak, Tak W.Wainberg, Zev A.Bedard, Philippe L.
- [7] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid TumorsONCOLOGIST, 2019, 24 (04): : 455 - E121Bendell, Johanna C.Patel, Manish R.Moore, Kathleen N.Chua, Cynthia C.Arkenau, Hendrik-TobiasDukart, GaryHarrow, KimLiang, Chris
- [8] A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumoursANNALS OF ONCOLOGY, 2020, 31 : S500 - S500Luke, J. J.Janku, F.Strauss, J.Olszanski, A. J.Leach, K.Radhakrishnan, I.Abbas, A.
- [9] A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Laurie, Scott AndrewJonker, Derek J.Edenfield, William JefferyStephenson, JoeKeller, DeborahHitron, MatthewLi, WeiLi, YouzhiGada, KeyurGao, YuanLi, Chiang
- [10] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumorsEJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69Calvo, E.Edelman, G.Baselga, J.Kwak, E.Scheffold, C.Nguyen, L.Shapiro, G. I.